Device Cardiac Surgery

Memo 4d

Payments companies reported to CMS as associated with Memo 4d. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$21Kassociated payments (2023-2025)
84clinicians with associated payments
1company reporting

By year

2023 $6,644
2024 $6,676
2025 $8,040

Payments reported as associated with Memo 4d, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Thoracic Surgery (Cardiothoracic Vascular Surgery) $17K
Surgery $1,948
Anesthesiology $296
Cardiovascular Disease $248
Surgical $232
Physician Assistant $115

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Memo 4d

These are the largest totals companies reported as associated with Memo 4d. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Sreekumar Subramanian Nashville, TN Thoracic Surgery (Cardiothoracic Vascular Surgery) $6,400.00
Tommaso Hinna Danesi Boston, MA Surgery $1,900.00
Mario Castillo-Sang Edgewood, KY Thoracic Surgery (Cardiothoracic Vascular Surgery) $1,411.80
Danny Ramzy Houston, TX Thoracic Surgery (Cardiothoracic Vascular Surgery) $1,200.00
Clarence Owen Brandon, FL Thoracic Surgery (Cardiothoracic Vascular Surgery) $980.85
Richard Ohye Denver, CO Thoracic Surgery (Cardiothoracic Vascular Surgery) $931.46
James Rankin Morgantown, WV Thoracic Surgery (Cardiothoracic Vascular Surgery) $664.15
Robert Gallegos Des Moines, IA Thoracic Surgery (Cardiothoracic Vascular Surgery) $405.61
Matthew Henn Columbus, OH Thoracic Surgery (Cardiothoracic Vascular Surgery) $387.76
Gundars Katlaps Tampa, FL Thoracic Surgery (Cardiothoracic Vascular Surgery) $320.03

Prescribed Memo 4d?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.